Universal CAR-γδT Cell Injection in the AML Patients

Hebei Senlang Biotechnology

Status

Unknown

Conditions

AML

Treatments

Biological: CAR--γδT cells

Study type

Interventional

Funder types

Industry

Identifiers

NCT05388305

CAR-γδT for AML

Details and patient eligibility

About

To evaluate the safety of general-purpose CAR-γδT cells in patients with refractory post-transplant relapsed AML.

Full description

To evaluate the efficacy and in vivo dynamics of general-purpose CAR-γδT cells in the treatment of refractory relapsed AML patients, and to explore the appropriate therapeutic dose and delivery mode.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The clinical diagnosis was difficult to treat recurrent acute myeloid leukemia；
Flow cytometry (FCM) or immunohistochemistry of tumor~ cells confirmed positive expression of CD123；
18 years old ≤ age ≤70 years old;
The expected survival from the date of informed consent is more than 3 months;
ECOG≤2;
The functions of vital organs shall meet the following conditions:
1. EF>50%, and no obvious ECG abnormality; 2) SpO2 90% or more; 3) Cr 2.5 ULN or less; 4) ALT And AST≤5ULN, TBil≤3ULN;
Subjects who plan to become pregnant must agree before study enrollment and after study duration of 6 months Use contraception; Inform the investigator immediately if the subject is pregnant or suspected to be pregnant;
Subject or guardian understands and signs the informed consent.

Exclusion criteria

Other diseases that have not been effectively controlled, including but not limited to persistent or poorly controlled infections and diseases Congestive heart failure, unstable angina pectoris, arrhythmias, poorly controlled lung disease Or mental illness;
Other active malignant tumors;
Complicated with severe infection that cannot be effectively controlled;
Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive, peripheral blood hepatitis B virus (HBV)DNA higher than the detection limit should be excluded; If hepatitis C virus (HCV) antibody positive, peripheral blood HCV RNA positive need to be eliminated; Cytomegalovirus (CMV)DNA positive; Epstein-barr virus DNA in peripheral blood was positive;
Human immunodeficiency virus (HIV) infection or syphilis infection;
Have a history of severe allergy to biological products (including antibiotics);
Acute graft-versus-host reaction (GVHD) was still present one month after discontinuation of immunosuppressant therapy Allogeneic hematopoietic stem cell transplantation patients;
Female subjects are in pregnancy and lactation;
Active autoimmune diseases requiring systemic immunosuppression;
Conditions that the investigator believes may increase the risk of the subject or interfere with the results of the test;